drugset / Trial / NCT07296341

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

NCT07296341

Phase 1/2 Recruiting 60 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid Tumors

Timeline

Start
2026-01-08
Primary completion
2027-10
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody
Comparator HRS-4642 Unknown
Comparator Gemcitabine Small molecule
Comparator Paclitaxel Small molecule

Indications

No indication recorded.